drugset
drugset / Trial / NCT05229588

Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

NCT05229588 ↗

Phase 2 Completed 8 enrolled HonorHealth Research Institute Jazz Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced Gastrointestinal Malignancies with DNA repair mutations.

Timeline

Start
2022-06-14
Primary completion
2025-08-04
Completion
2025-08-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurbinectedin Other / unclassified 3.2 mg/m2 Intravenous

Indications

digestive system cancer